Insider Buying: InMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Purchases $11,048.31 in Stock

Posted by Francis Steltz on Oct 5th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Adar1 Capital Management, Llc bought 8,307 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was purchased at an average price of $1.33 per share, with a total value of $11,048.31. Following the completion of the purchase, the insider owned 916,839 shares in the company, valued at approximately $1,219,395.87. This trade represents a 0.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Monday, October 5th, Adar1 Capital Management, Llc purchased 18,182 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.33 per share, for a total transaction of $24,182.06.
On Thursday, October 1st, Adar1 Capital Management, Llc purchased 16,431 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.33 per share, with a total value of $21,853.23.
On Monday, September 14th, Adar1 Capital Management, Llc purchased 28,505 shares of InMed Pharmaceuticals stock. The shares were acquired at an average price of $1.29 per share, for a total transaction of $36,771.45.
On Wednesday, September 16th, Adar1 Capital Management, Llc acquired 8,340 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.29 per share, for a total transaction of $10,758.60.
On Tuesday, September 15th, Adar1 Capital Management, Llc acquired 54,256 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.30 per share, with a total value of $70,532.80.

InMed Pharmaceuticals Stock Performance

Shares of NASDAQ:INM remained flat at $1.33 during midday trading on Monday. The stock had a trading volume of 29,570 shares, compared to its average volume of 887,905. The company has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $1.26. InMed Pharmaceuticals Inc. has a 52-week low of $0.57 and a 52-week high of $2.50. The stock has a market cap of $4.40 million, a P/E ratio of -0.81 and a beta of 0.93.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

View Our Latest Stock Report on INM

Institutional Investors Weigh In On InMed Pharmaceuticals

A hedge fund recently bought a new position in InMed Pharmaceuticals stock. Montanova Capital LLC bought a new stake in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $155,000. Montanova Capital LLC owned approximately 3.02% of InMed Pharmaceuticals at the end of the most recent quarter. 20.12% of the stock is currently owned by hedge funds and other institutional investors.

InMed Pharmaceuticals Company Profile

(Get Free Report)

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of pharmaceutical products based on rare cannabinoids. The company combines cannabinoid science with drug-development expertise to investigate potential treatments for diseases with significant unmet medical needs.

Its research pipeline has included INM-901, an investigational rare-cannabinoid therapy being developed for Alzheimer’s disease, as well as earlier programs targeting conditions such as epidermolysis bullosa and glaucoma.